Civil Litigation,
Antitrust & Trade Reg.
May 9, 2022
Bristol-Myers gets final OK for settlement with end-payors
The class claimed Gilead Sciences Inc. and its alleged co-conspirator, Bristol-Myers Squibb Co., violated antitrust and consumer protection laws when they allegedly conspired to “monopolize and restrain trade” in the market for HIV and combination antiretroviral therapy medication.
A judge gave final approval for a $2.5 million settlement between defendant Bristol-Myers Squibb Co. and a class of end-payor plaintiffs Friday.
The class claimed Gilead Sciences Inc. and its alleged co-conspirator, Bristol-Myers Squibb Co., violated antitrust and consumer protection laws when they allegedly conspired to “monopolize and restrain trade” in the market for HIV and combination antiretroviral therapy medication.
$95
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In